Usage and dosage of Olaparib

The recommended dose of olaparib is 300 mg taken orally twice daily with or without food. If a patient misses a dose of olaparib, instruct the patient to take the next dose at the scheduled time. Do not chew, crush, dissolve, or split tablets.

(1) First-line maintenance treatment for BRCA-mutated advanced ovarian cancer:

Continue treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with complete response (no radiographic evidence of disease) at 2 years should discontinue treatment. Patients with evidence of disease at 2 years may be treated beyond 2 years if the treating provider believes they will derive further benefit from continued treatment.

(2) First-line maintenance therapy with bevacizumabHRD-positive advanced ovarian cancer:

Continue treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with complete response (no radiographic evidence of disease) at 2 years should discontinue treatment. Patients with evidence of disease at 2 years may be treated beyond 2 years if the treating provider believes they will derive further benefit from continued treatment. The recommended dose of bevacizumab when administered with olaparib is 15 mg/kg every three weeks Bevacizumab should be continued for 15 months, including during chemotherapy and maintenance.

(3) GermlineAdjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer:

Continue treatment for a total of1 year or until disease recurrence or unacceptable toxicity, whichever occurs first. Patients receiving olaparib for hormone receptor-positive HER2-negative breast cancer should continue to receive concomitant endocrine therapy in accordance with current clinical practice guidelines.

(4) Recurrent ovarian cancer,HER2-negative metastatic breast cancer, metastatic pancreatic cancer, and HRR gene-mutated metastatic castration-resistant prostate cancer: Continue treatment until disease progression or unacceptable toxicity occurs.

(5) BRCA-mutated metastatic castration-resistant prostate cancer combined with abiraterone and prednisone or prednisolone:

Continue treatment until disease progression or unacceptable toxicity occurs. When used with olaparib, the recommended dose of abiraterone is 1000 mg taken orally once daily. Abiraterone should be taken orally in combination with prednisone or prednisolone 5 mg twice daily. Patients should also receive concomitant gonadotropin-releasing hormone (GnRH) analog therapy or should undergo bilateral orchiectomy.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The price of 150mg*120 tablets per box produced by Bangladesh pharmaceutical factory may be around 4,000 RMB 90 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of Olaparib original drug. For more drug information and specific prices, please consult a medical consultant.